Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, pomalidomide (Imnovid®) cannot be endorsed for use within NHS Wales in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide. |
||
|
||
Medicine details |
||
| Medicine name | pomalidomide (Imnovid®) | |
| Formulation | 1 mg capsule, 2 mg capsule, 3 mg capsule, 4 mg capsule | |
| Reference number | 3515 | |
| Indication | Foe use in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide. |
|
| Company | Celgene Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | 16/09/2019 | |
| Date of issue | 18/09/2019 | |